Dr Leonardo Magneschi is the Head of Molecular Biology at Ingenza. In 2020 he and his team embarked upon a project in conjunction with the University of Oxford and the Centre for Process Innovation (CPI) to rapidly formulate a highly effective vaccine against SARS-CoV-2, the virus responsible for the COVID-19 pandemic. New research published in Science by…
Advances in engineering biology are creating an ever-expanding toolkit and evolving infrastructure that can conceptualise, deliver and scale solutions to address a wide range of biological, chemical and even social problems. As society emerges from a global pandemic, two of the…
Ingenza is pleased to welcome Steve Jones as he takes on the role of Chief Financial Officer (CFO), effective immediately. Steve has over 25 years of industry experience and know-how, after holding several senior finance roles across a wide range of…
Edinburgh-based Ingenza, a pioneer in engineering biology, is delighted to celebrate its 20 year anniversary this month. The milestone will be marked with an event on the 20th of April for esteemed colleagues and guests, providing an opportunity to reflect on the…
Ingenza has undergone significant transformation and growth since its inception in 2003, which would not have been possible without a talented and multifaceted team lending their collective expertise to the development and commercialisation of biobased products. New positions and responsibilities…
Ingenza is excited to welcome Dr Mark Chadwick to the team as Strategic Business Advisor. Mark will bring extensive industry expertise to his new position at Ingenza, acquired over 30 years from a variety of roles within small growth companies,…
Edinburgh-based Ingenza, a pioneer in engineering biology, is pleased to announce the appointment of Dr Ian Shott CBE, FREng to the board as Executive Chairman. Ian joins Ingenza with over 35 years of experience in the global life science and biotechnology…
Industrial biotech specialist Ingenza is delighted to announce that it is collaborating with clinical-stage biopharmaceutical company Amplifica Holdings Group, Inc. to develop an innovative treatment to address androgenic alopecia. Amplifica has partnered with Ingenza to advance the development of its…
Dr Connor Bowen is a Senior Scientist working within the molecular biology team at Ingenza. He received his undergraduate degree from the University of Dundee, and followed it up with a PhD and post doc at the same institution, studying Serratia…
Ingenza has delivered a new, proprietary biomanufacturing process for human recombinant factor VIII (rhFVIII) to Scottish biotechnology company ProFactor Pharma Ltd (PFP), which will considerably increase global access to low-cost treatment for haemophilia A. The novel bioprocess underpins PFP’s recent…